Skip to Content

'
Xifeng Wu

Present Title & Affiliation

Primary Appointment

Department Chair, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Center for Translational and Public Health Genomics, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Member, The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, Houston, TX
Executive Sponsor, Institutional Patient History Database (PHDB), Database, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Division of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas School of Public Health, Houston, TX

Bio Statement

The overarching goal of my translational research program is to construct comprehensive, clinically applicable risk prediction models along the entire cancer continuum, from etiology to screening, prognosis, treatment response and survivorship. To accomplish the program’s objectives, my laboratory practices multidisciplinary research that bridges the fields of basic science, epidemiology, biostatistics, and clinical research. We devise integrative strategies that enable risk assessment, early detection and delineation of early- and late-stage clinical outcomes. Our investigations channel towards identification and validation of clinically useful prognostic and predictive biomarkers, and discovery of molecular targets with therapeutic potential.  Assimilation of biomarkers with epidemiological, clinical, phenotypic, and genetic information enables development of accurate and reliable personalized cancer risk prediction models that inform clinical care and empower clinical risk stratification along the cancer care continuum. Our multifaceted and highly innovative research has yielded novel and signifcant findings across malignancies, including in bladder cancer, lung cancer, renal cell carcinoma, and gastrointestinal cancer.

We conduct and lead a number of high-profile initiatives that yield significant institutional-wide impact. The Center for Translational and Public Health Genomics is establishing a unique and prospective Cancer Patient Cohort comprised of all newly-presenting patients at MD Anderson. The cohort is specifically designed to enable address of determinants impacting cancer symptoms, prognosis, progression, treatment response, toxicity, survival, and quality of life. The cohort infrastructure encompasses an all-inclusive biorepository, the Blood Specimen Research Resource, which is seamlessly linked to the Patient History Database (PHDB). The electronic PHDB supports epidemiologic information related to core risks and exposures, and integrates all data with other institutional patient data resources.

My group engages in a number of major collaborative efforts. The Premalignant Genome Atlas program, conducted in concert with the Duncan Family Institute, assesses the full spectrum of risk factors contributing to initiation and progression of precancerous lesions. On another front, my collaboration with MJ Health facilitates both comprehensive and prospective analysis of risk factors associated with cancer and other diseases by query of the large MJ Cohort, a unique patient database established in association with a major health screening program conducted in Taiwan. At the institutional level, my group is heavily involved in multiple SPORE projects focusing on different cancer sites.

We successfully execute contemporary epidemiologic strategies across the cancer continuum by employing advanced, state-of-the-art technologies including high- and mid-throughput assay platforms for genotyping, whole-genome expression profiling, copy number analysis, next-generation sequencing, mitochondrial DNA analysis, and metabolome profiling.

Major Accomplishments

  • Established and led a large, multi-disciplinary, research team that includes data collection, biospecimen processing, , molecular and genomics lab, and statistical analysis
  • Has a stellar record of extramural funding from NCI and CPRIT; published over 300 peer-reviewed papers, invited articles, and editorial articles.
  • Extensive intra- and inter-institutional and international collaborations: co-PI of the Head and Neck SPORE,  project leader in 4 SPOREs (lung, bladder, prostate, and head and neck) and 1 P01, and Chair of the International Consortium of Bladder Cancer
  • Established the largest ongoing case control studies in the U.S. for bladder, esophageal, and renal cancer and one of the largest clinical outcome studies for lung cancer.
  • Published seminal papers on identifying genetic susceptibility loci for cancer risk and  survival
  • Established: Center for Translational and Public Health Genomics; institutional Blood Specimen Research Resource, a biorepository for residual blood samples of all newly diagnosed patients; biorepository for long-term cancer patient survivors; and propelled implementation of electronic Patient History Database; Co-leader of the Premalignant Genome Atlas program in the Duncan Family Institute for Cancer Prevention and Risk Assessment
  • Scientific director for a large prospective health screening cohort, MJ Cohort in Taiwan

Research Interests

  • Genetic basis of cancer and interactions with environment, diet, and physical activitiy
  • Integrative risk prediction models for cancer development, prognosis, and treament response
  • Premalignant lesions: risk and progression to cancer

Office Address

The University of Texas MD Anderson Cancer Center
1155 Herman P. Pressler Blvd.
Unit Number: 1340
Houston, TX 77030
Room Number: CPB4.3301
Phone: (713) 745-2485
Fax: (713) 792-4657
Email: xwu@mdanderson.org

Education & Training

Degree-Granting Education

1994 The University of Texas Health Science Center at Houston School of Public Health, Houston, TX, PHD, Epidemiology
1987 Zhejiang University, Hangzhou, China, MS, Industrial Hygiene and Occupational Diseases
1984 Fudan University, Shanghai, China, MD, Medicine

Postgraduate Training

1990-1991 Postdoctoral Fellowship, National Laboratory of Industrial Environment and Risk Analysis (INERIS), Verneuil-en-Halatte, France

Board Certifications

2007 MD Anderson Cancer Center, Faculty Leadership Academy
6/2005 Center for Creative Leadership Training, Women's Leadership Program
1994 National Cytogenetic Specialist Certification

Experience/Service

Academic Appointments

Professor, Department of Epidemiology, The University of Texas School of Public Health at Houston, Houston, TX, 2008-2010
Associate Professor, Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2000-2004
Assistant Professor, Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1995-2000

Institutional Committee Activities

Member, Bladder Cancer SPORE Executive Committee, 2002-present

Honors and Awards

2012-present Wall of Science Publication Gallery Inclusion, The University of Texas MD Anderson Cancer Center
2011 Robert M. Chamberlain Distinguished Mentor Award, The University of Texas MD Anderson Cancer Center
2008-present Betty B. Marcus Chair in Cancer Prevention, MD Anderson Cancer Center
2008-present Senior Fellow of the MD Anderson Research Trust, The University of Texas MD Anderson Cancer Center
2008 Julie and Ben Rogers Award for Excellence, The University of Texas MD Anderson Cancer Center
2008 The Margaret and James A. Elkins, Jr. Faculty Achievement Award in Cancer Prevention, The University of Texas MD Anderson Cancer Center
2006-2008 Ashbel Smith Professorship, The University of Texas
2002 Faculty Scholar Award, The University of Texas MD Anderson Cancer Center
1995 Richard C. Devereaux Award for Outstanding Young Investigators in Lung Cancer Prevention, Research Foundation of America
1993 D. Jack Kilian Scholarship
1989 Zhejiang Scientific and Technologic Award

Selected Publications

Peer-Reviewed Original Research Articles

1. Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E. MicroRNA Expression Signatures during Malignant Progression from Barrett's Esophagus to Esophageal Adenocarcinoma. Cancer Prev Res (Phila) 6(3):196-205, 3/2013. PMCID: PMC3608471.
2. Shu X, Lin J, Wood CG, Tannir NM, Wu X. Energy Balance, Polymorphisms in the mTOR Pathway, and Renal Cell Carcinoma Risk. J Natl Cancer Inst. e-Pub 2/2013. PMID: 23378641.
3. Wen CP, Tsai MK, Wai JP, Wu X. Promoting increased physical activity and reduced inactivity - Authors' reply. Lancet 381(9861):114-5, 1/2013. PMID: 23312751.
4. Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Etzel C, Huang M, Hsu CY, Ye Y, Mishra L, Hawk E, Wu X. Hepatocellular Carcinoma Risk Prediction Model for the General Population: The Predictive Power of Transaminases. J Natl Cancer Inst 104(20):1599-611, 10/2012. PMID: 23073549.
5. Pu X, Ye Y, Spitz MR, Wang L, Gu J, Lippman SM, Hildebrandt MA, Hong WK, Minna JD, Roth JA, Yang P, Wu X. Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study. Clin Cancer Res. e-Pub 9/2012. PMID: 22977190.
6. Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, Huang M, Calin GA, Wang D, Dubois RN, Hawk ET, Wu X. Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients. Clin Cancer Res 18(14):3982-91, 7/2012. e-Pub 6/2012. PMID: 22661538.
7. Hildebrandt MA, Lippman SM, Etzel CJ, Kim E, Lee JJ, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X. Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention. Clin Cancer Res 18(13):3705-13, 7/2012. e-Pub 5/2012. PMCID: PMC3404728.
8. Spitz MR, Gorlov IP, Dong Q, Wu X, Chen W, Chang DW, Etzel CJ, Caporaso NE, Zhao Y, Christiani DC, Brennan P, Albanes D, Shi J, Thun M, Landi MT, Amos CI. Multistage Analysis of Variants in the Inflammation Pathway and Lung Cancer Risk in Smokers. Cancer Epidemiol Biomarkers Prev 21(7):1213-21, 7/2012. e-Pub 5/2012. PMID: 22573796.
9. Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L, Farci P, Mishra L. Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. e-Pub 6/2012. PMID: 22710573.
10. Fu YP, Kohaar I, Rothman N, Earl J, Figueroa JD, Ye Y, Malats N, Tang W, Liu L, Garcia-Closas M, Muchmore B, Chatterjee N, Tarway M, Kogevinas M, Porter-Gill P, Baris D, Mumy A, Albanes D, Purdue MP, Hutchinson A, Carrato A, Tardón A, Serra C, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Diver WR, Gapstur SM, Thun MJ, Virtamo J, Chanock SJ, Fraumeni JF, Silverman DT, Wu X, Real FX, Prokunina-Olsson L. Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. Proc Natl Acad Sci U S A 109(13):4974-9, 3/2012. e-Pub 3/2012. PMCID: PMC3324016.
11. Lin J, Forman MR, Wang J, Grossman HB, Chen M, Dinney CP, Hawk ET, Wu X. Intake of red meat and heterocyclic amines, metabolic pathway genes, and bladder cancer risk. Int J Cancer. e-Pub 1/2012. PMID: 22261697.
12. Wu X, Scelo G, Purdue MP, Rothman N, Johansson M, Ye Y, Wang Z, Zelenika D, Moore LE, Wood CG, Prokhortchouk E, Gaborieau V, Jacobs KB, Chow WH, Toro JR, Zaridze D, Lin J, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Jinga V, Bencko V, Slamova A, Holcatova I, Navratilova M, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL, Boeing H, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, Duell EJ, Quirós JR, Sanchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Ljungberg B, Overvad K, Tjønneland A, Romieu I, Riboli E, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Virtamo J, Vatten L, Hveem K, Fletcher T, Koppova K, Cussenot O, Cancel-Tassin G, Benhamou S, Hildebrandt MA, Pu X, Foglio M, Lechner D, Hutchinson A, Yeager M, Fraumeni JF, Lathrop M, Skryabin KG, McKay JD, Gu J, Brennan P, Chanock SJ. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet. e-Pub 11/2011. PMID: 22010048.
13. Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP, Chatterjee N, Prokunina-Olsson L, Wang Z, Lin J, Real FX, Jacobs KB, Baris D, Thun M, De Vivo I, Albanes D, Purdue MP, Kogevinas M, Kamat AM, Lerner SP, Barton Grossman H, Gu J, Pu X, Hutchinson A, Fu YP, Burdett L, Yeager M, Tang W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Grubb R, Black A, Jacobs EJ, Ryan Diver W, Gapstur SM, Weinstein SJ, Virtamo J, Hunter DJ, Caporaso N, Teresa Landi M, Fraumeni JF, Silverman DT, Chanock SJ, Wu X. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet 20(21):4282-9, 11/2011. e-Pub 8/2011. PMCID: PMC3188994.
14. Wen CP, Wai JP, Tsai MK, Yang YC, Cheng TY, Lee MC, Chan HT, Tsao CK, Tsai SP, Wu X. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet 378(9798):1244-53, 10/2011. e-Pub 8/2011. PMID: 21846575.
15. Hinch AG, Tandon A, Patterson N, Song Y, Rohland N, Palmer CD, Chen GK, Wang K, Buxbaum SG, Akylbekova EL, Aldrich MC, Ambrosone CB, Amos C, Bandera EV, Berndt SI, Bernstein L, Blot WJ, Bock CH, Boerwinkle E, Cai Q, Caporaso N, Casey G, Cupples LA, Deming SL, Diver WR, Divers J, Fornage M, Gillanders EM, Glessner J, Harris CC, Hu JJ, Ingles SA, Isaacs W, John EM, Kao WH, Keating B, Kittles RA, Kolonel LN, Larkin E, Le Marchand L, McNeill LH, Millikan RC, Murphy A, Musani S, Neslund-Dudas C, Nyante S, Papanicolaou GJ, Press MF, Psaty BM, Reiner AP, Rich SS, Rodriguez-Gil JL, Rotter JI, Rybicki BA, Schwartz AG, Signorello LB, Spitz M, Strom SS, Thun MJ, Tucker MA, Wang Z, Wiencke JK, Witte JS, Wrensch M, Wu X, Yamamura Y, Zanetti KA, Zheng W, Ziegler RG, Zhu X, Redline S, Hirschhorn JN, Henderson BE, Taylor HA, Price AL, Hakonarson H, Chanock SJ, Haiman CA, Wilson JG, Reich D, Myers SR. The landscape of recombination in African Americans. Nature 476(7359):170-5, 8/2011. e-Pub 7/2011. PMCID: PMC3154982.
16. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 103(10):817-25, 5/2011. e-Pub 4/2011. PMCID: PMC3096796.
17. Gu J, Chen M, Shete S, Amos CI, Kamat A, Ye Y, Lin J, Dinney CP, Wu X. A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila) 4(4):514-21, 4/2011. e-Pub 4/2011. PMCID: PMC3076128.
18. Gu J, Ye Y, Spitz MR, Lin J, Kiemeney LA, Xing J, Hildebrandt MA, Ki Hong W, Amos CI, Wu X. A genetic variant near the PMAIP1/Noxa gene is associated with increased bleomycin sensitivity. Hum Mol Genet 20(4):820-6, 2/2011. e-Pub 11/2010. PMCID: PMC3024041.
19. Lee JJ, Wu X, Hildebrandt MA, Yang H, Khuri FR, Kim E, Gu J, Ye Y, Lotan R, Spitz MR, Hong WK. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 4(2):185-93, 2/2011. PMID: 21292633.
20. Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, Moore LE, Prokhortchouk E, Wu X, Kiemeney LA, Gaborieau V, Jacobs KB, Chow WH, Zaridze D, Matveev V, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Bucur A, Bencko V, Foretova L, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL, Boeing H, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, Duell EJ, Quirós JR, Sanchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Ljungberg B, Overvad K, Tjønneland A, Romieu I, Riboli E, Mukeria A, Shangina O, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Weinstein SJ, Virtamo J, Vatten L, Hveem K, Njølstad I, Tell GS, Stoltenberg C, Kumar R, Koppova K, Cussenot O, Benhamou S, Oosterwijk E, Vermeulen SH, Aben KK, van der Marel SL, Ye Y, Wood CG, Pu X, Mazur AM, Boulygina ES, Chekanov NN, Foglio M, Lechner D, Gut I, Heath S, Blanche H, Hutchinson A, Thomas G, Wang Z, Yeager M, Fraumeni JF, Skryabin KG, McKay JD, Rothman N, Chanock SJ, Lathrop M, Brennan P. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet 43(1):60-5, 1/2011. e-Pub 12/2010. PMID: 21131975.
21. Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, Gu J, Wu X, Lu K. Genetic Variants in MicroRNA Biosynthesis Pathways and Binding Sites Modify Ovarian Cancer Risk, Survival, and Treatment Response. Cancer Res 70(23):9765-76, 12/2010. e-Pub 11/2010. PMID: 21118967.
22. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeney LA, Vineis P, De Vivo I, Albanes D, Purdue MP, Rafnar T, Hildebrandt MA, Kiltie AE, Cussenot O, Golka K, Kumar R, Taylor JA, Mayordomo JI, Jacobs KB, Kogevinas M, Hutchinson A, Wang Z, Fu YP, Prokunina-Olsson L, Burdett L, Yeager M, Wheeler W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Grubb R, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Cortessis VK, Gago-Dominguez M, Pike MC, Stern MC, Yuan JM, Hunter DJ, McGrath M, Dinney CP, Czerniak B, Chen M, Yang H, Vermeulen SH, Aben KK, Witjes JA, Makkinje RR, Sulem P, Besenbacher S, Stefansson K, Riboli E, Brennan P, Panico S, Navarro C, Allen NE, Bueno-de-Mesquita HB, Trichopoulos D, Caporaso N, Landi MT, Canzian F, Ljungberg B, Tjonneland A, Clavel-Chapelon F, Bishop DT, Teo MT, Knowles MA, Guarrera S, Polidoro S, Ricceri F, Sacerdote C, Allione A, Cancel-Tassin G, Selinski S, Hengstler JG, Dietrich H, Fletcher T, Rudnai P, Gurzau E, Koppova K, Bolick SC, Godfrey A, Xu Z, Sanz-Velez JI, D García-Prats M, Sanchez M, Valdivia G, Porru S, Benhamou S, Hoover RN, Fraumeni JF, Silverman DT, Chanock SJ. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 42(11):978-84, 11/2010. e-Pub 10/2010. PMID: 20972438.
23. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu X. Chromosomal Aberrations Predict Malignant Progression of Esophageal Adenocarcinoma: a Genome-wide High-Density SNP Array Analysis. Cancer Prev Res (Phila) 3(9):1176-86, 9/2010. e-Pub 7/2010. PMID: 20651033.
24. Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli T, Wood CG, Wu X. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene. e-Pub 8/2010.
25. Amos CI, Gorlov IP, Dong Q, Wu X, Zhang H, Lu EY, Scheet P, Greisinger AJ, Mills GB, Spitz MR. Nicotinic Acetylcholine Receptor Region on Chromosome 15q25 and Lung Cancer Risk Among African Americans: A Case-Control Study. J Natl Cancer Inst 102(15):1199-205, 8/2010. e-Pub 6/2010. PMCID: PMC2914761.
26. Truong T, Hung RJ, Amos CI, Wu X, Bickeböller H, Rosenberger A, Sauter W, Illig T, Wichmann HE, Risch A, Dienemann H, Kaaks R, Yang P, Jiang R, Wiencke JK, Wrensch M, Hansen H, Kelsey KT, Matsuo K, Tajima K, Schwartz AG, Wenzlaff A, Seow A, Ying C, Staratschek-Jox A, Nürnberg P, Stoelben E, Wolf J, Lazarus P, Muscat JE, Gallagher CJ, Zienolddiny S, Haugen A, van der Heijden HF, Kiemeney LA, Isla D, Mayordomo JI, Rafnar T, Stefansson K, Zhang ZF, Chang SC, Kim JH, Hong YC, Duell EJ, Andrew AS, Lejbkowicz F, Rennert G, Müller H, Brenner H, Le Marchand L, Benhamou S, Bouchardy C, Teare MD, Xue X, McLaughlin J, Liu G, McKay JD, Brennan P, Spitz MR. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst 102(13):959-71, 7/2010. e-Pub 6/2010. PMCID: PMC2897877.
27. Lin J, Wang J, Greisinger AJ, Grossman HB, Forman MR, Dinney CP, Hawk ET, Wu X. Energy Balance, the PI3K-AKT-mTOR Pathway Genes and the Risk of Bladder Cancer. Cancer Prev Res (Phila) 3(4):505-17, 4/2010. e-Pub 3/2010. PMCID: PMC2867666.
28. Li Y, Sheu CC, Ye Y, de Andrade M, Wang L, Chang SC, Aubry MC, Aakre JA, Allen MS, Chen F, Cunningham JM, Deschamps C, Jiang R, Lin J, Marks RS, Pankratz VS, Su L, Li Y, Sun Z, Tang H, Vasmatzis G, Harris CC, Spitz MR, Jen J, Wang R, Zhang ZF, Christiani DC, Wu X, Yang P. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 11(4):321-30, 4/2010. e-Pub 3/2010. PMCID: PMC2945218.
29. Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, Ajani JA, Wu X. MicroRNA Expression Signatures in Barrett's Esophagus and Esophageal Adenocarcinoma. Clin Cancer Res 15(18):5744-52, 9/2009. e-Pub 9/2009. PMCID: PMC2745487.
30. Wu X, Spitz MR, Lee JJ, Lippman SM, Ye Y, Yang H, Khuri FR, Kim E, Gu J, Lotan R, Hong WK. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila Pa) 2(7):617-24, 7/2009. PMID: 19584075.
31. Xing J, Ajani JA, Chen M, Izzo J, Lin J, Chen Z, Gu J, Wu X. Constitutive Short Telomere Length of Chromosome 17p and 12q but not 11q and 2p Is Associated with an Increased Risk for Esophageal Cancer. Cancer Prev Res (Phila Pa) 2(5):459-65, 5/2009. e-Pub 4/2009. PMCID: PMC2701666.
32. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X.. Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway are Associated with Clinical Outcomes in Esophageal Cancer Patients Treated with Chemoradiotherapy. J Clin Oncol 27(6):857-71, 2/2009. e-Pub 1/2009. PMCID: PMC2738430.
33. Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med 7:45, 2009. PMCID: PMC2724494.
34. Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, Seminara D, Yoshida T, Saeki N, Andrew AS, Dinney CP, Czerniak B, Zhang ZF, Kiltie AE, Bishop DT, Vineis P, Porru S, Buntinx F, Kellen E, Zeegers MP, Kumar R, Rudnai P, Gurzau E, Koppova K, Mayordomo JI, Sanchez M, Saez B, Lindblom A, de Verdier P, Steineck G, Mills GB, Schned A, Guarrera S, Polidoro S, Chang SC, Lin J, Chang DW, Hale KS, Majewski T, Grossman HB, Thorlacius S, Thorsteinsdottir U, Aben KK, Witjes JA, Stefansson K, Amos CI, Karagas MR, Gu J. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 41(9):991-5, 2009. e-Pub 8/2009. PMID: 19648920.
35. Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, Qureshi M, Dong Q, Gu X, Chen WV, Spitz MR, Eisen T, Amos CI, Houlston RS. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 40(12):1407-9, 12/2008. e-Pub 11/2008. PMCID: PMC2695928.
36. Horikawa Y, Wood CG, Yang H, Zhao H, Ye Y, Gu J, Lin J, Habuchi T, Wu X. Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res 14(23):7956-62, 12/2008. PMCID: PMC2650498.
37. Wu X, Lu C, Ye Y, Chang J, Yang H, Lin J, Gu J, Hong WK, Stewart D, Spitz MR. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 18(11):955-65, 11/2008. PMCID: PMC2665725.
38. Spitz MR, Amos CI, Dong Q, Lin J, Wu X. The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst 100(21):1552-6, 11/2008. e-Pub 10/2008. PMCID: PMC2720751.
39. Spitz MR, Etzel CJ, Dong Q, Amos CI, Wei Q, Wu X, Hong WK. An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila Pa) 1(4):250-4, 9/2008. PMCID: PMC2854404.
40. Liu P, Vikis HG, Wang D, Lu Y, Wang Y, Schwartz AG, Pinney SM, Yang P, de Andrade M, Petersen GM, Wiest JS, Fain PR, Gazdar A, Gaba C, Rothschild H, Mandal D, Coons T, Lee J, Kupert E, Seminara D, Minna J, Bailey-Wilson JE, Wu X, Spitz MR, Eisen T, Houlston RS, Amos CI, Anderson MW, You M. Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst 100(18):1326-30, 9/2008. e-Pub 9/2008. PMCID: PMC2538550.
41. Xing J, Chen M, Wood CG, Lin J, Spitz MR, Ma J, Amos CI, Shields PG, Benowitz NL, Gu J, de Andrade M, Swan GE, Wu X. Mitochondrial DNA Content: Its Genetic Heritability and Association with Renal Cell Carcinoma. J Natl Cancer Inst 100(15):1104-12, 8/2008. e-Pub 7/2008. PMCID: PMC2720693.
42. Reyes-Gibby CC, Wu X, Spitz M, Kurzrock R, Fisch M, Bruera E, Shete S. Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol 9(8):777-85, 8/2008. PMID: 18672213.
43. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, Sullivan K, Matakidou A, Wang Y, Mills G, Doheny K, Tsai YY, Chen WV, Shete S, Spitz MR, Houlston RS. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40(5):616-22, 5/2008. e-Pub 4/2008. PMCID: PMC2713680.
44. Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res 68(7):2530-7, 4/2008. PMID: 18381463.
45. Xing J, Stewart DJ, Gu J, Lu C, Spitz MR, Wu X. Expression of methylation-related genes predicts overall survival in patients with non-small cell lung cancer. Br J Cancer 98:1716-22, 2008.
46. Wu X, Lin J, Grossman HB, Huang M, Gu J, Etzel CJ, Amos CI, Dinney CP, Spitz MR. Projecting Individualized Probabilities of Developing Bladder Cancer in Caucasians. J Clin Oncol 25(31):4974-81, 11/2007. PMID: 17971596.
47. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, Shete S, Etzel CJ. A risk model for prediction of lung cancer. J Natl Cancer Inst 99(9):715-26, 5/2007. PMID: 17470739.
48. Zhao H, Lin J, Grossman HB, Hernandez LM, Dinney CP, Wu X. Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk. Int J Cancer 120(10):2208-13, 5/2007. PMID: 17290402.
49. Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR, Wu X. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 12(24):7329-38, 2006. PMID: 17189404.
50. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, Spitz MR. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 78(3):464-79, 2006. PMID: 16465622.
51. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24(23):3789-98, 2006. PMID: 16785472.
52. Wu X, Spitz MR, Amos CI, Lin J, Shao L, Gu J, de Andrade M, Benowitz NL, Shields PG, Swan GE. Mutagen sensitivity has high heritability: evidence from a twin study. Cancer Res 66(12):5993-6, 2006. PMID: 16778168.
53. Schabath MB, Spitz MR, Lerner SP, Pillow PC, Hernandez LM, Delclos GL, Grossman HB, Wu X. Case-control analysis of dietary folate and risk of bladder cancer. Nutr Cancer 53(2):144-51, 2005. PMID: 16573375.
54. Schabath MB, Hernandez LM, Wu X, Pillow PC, Spitz MR. Dietary phytoestrogens and lung cancer risk. JAMA 294(12):1493-504, 2005. PMID: 16189362.
55. Schabath MB, Delclos GL, Martynowicz MM, Greisinger AJ, Lu C, Wu X, Spitz MR. Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am J Epidemiol 161(5):412-22, 2005. PMID: 15718477.
56. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 23(24):5746-56, 2005. PMID: 16110031.
57. Zhu Y, Spitz MR, Amos CI, Lin J, Schabath MB, Wu X. An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Cancer Res 64(6):2251-7, 2004. PMID: 15026370.
58. Schabath MB, Grossman HB, Delclos GL, Hernandez LM, Day RS, Davis BR, Lerner SP, Spitz MR, Wu X. Dietary carotenoids and genetic instability modify bladder cancer risk. J Nutr 134(12):3362-9, 2004. PMID: 15570038.
59. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 10(1 Pt 1):113-23, 2004. PMID: 14734459.
60. Park SJ, Zhao H, Spitz MR, Grossman HB, Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 536(1-2):131-7, 4/2003. PMID: 12694753.
61. Schabath MB, Spitz MR, Grossman HB, Zhang K, Dinney CP, Zheng PJ, Wu X. Genetic instability in bladder cancer assessed by the comet assay. J Natl Cancer Inst 95(7):540-7, 2003. PMID: 12671022.
62. Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, Luo S, Hong WK, Spitz MR. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 95(16):1211-8, 2003. PMID: 12928346.
63. Wu X, Lippman SM, Lee JJ, Zhu Y, Wei QV, Thomas M, Hong WK, Spitz MR. Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res 62(10):2813-8, 5/2002. PMID: 12019158.
64. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J Natl Cancer Inst 94(9):681-90, 5/2002. PMID: 11983757.
65. Zhao H, Spitz MR, Tomlinson GE, Zhang H, Minna JD, Wu X . Gamma-radiation-induced G2 delay, apoptosis, and p53 response as potential susceptibility markers for lung cancer. Cancer Res 61:7819-24, 2001. PMID: 11691798.
66. Wu X, Yu H, Amos CI, Hong WK, Spitz MR. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst 92(9):737-43, 5/2000. PMID: 10793110.
67. Wu X, Hudmon KS, Detry MA, Chamberlain RM, Spitz MR. D2 dopamine receptor gene polymorphisms among African-Americans and Mexican-Americans: a lung cancer case-control study. Cancer Epidemiol Biomarkers Prev 9:1021-6, 2000. PMID: 11045783.
68. Wu X, Yu H, Amos CI, Hong WK, Spitz MR. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst 92:737-43, 2000. PMID: 10984281.
69. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91:151-6, 1999. PMID: 9923856.
70. Wu X, Gu J, Hong WK, Lee JJ, Amos CI, Jiang H, Winn RJ, Fu KK, Cooper J, Spitz MR. Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst 90:1393-9, 1998. PMID: 9747870.
71. Wu X, Zhao Y, Honn SE, Tomlinson GE, Minna JD, Hong WK, Spitz MR. Benzo[a]pyrene diol epoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer. Cancer Res 58:1605-8, 1998. PMID: 9563468.
72. Spitz MR, Shi H, Yang F, Hudmon KS, Jiang H, Chamberlain RM, Amos CI, Wan Y, Cinciripini P, Hong WK, Wu X. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 90:358-63, 1998. PMID: 9498485.
73. King TM, Trizna Z, Wu X, Amos CI, Fueger RH, Fueger JJ, Fritsche HA, Hsu TC, Winn R, Spitz MR. A clinical trial to evaluate the effect of vitamin C supplementation on in vitro mutagen sensitivity. The University of Texas M. D. Anderson Clinical Community Oncology Program Network. Cancer Epidemiol Biomarkers Prev 6:537-42, 1997. PMID: 9232342.
74. Wu X, Hsu TC, Annegers JF, Amos CI, Fueger JJ, Spitz MR. A case-control study of nonrandom distribution of bleomycin-induced chromatid breaks in lymphocytes of lung cancer cases. Cancer Res 55(3):557-61, 2/1995. PMID: 7530597.
75. Strom SS, Wu X, Sigurdson AJ, Hsu TC, Fueger JJ, Lopez J, Tee PG, Spitz MR. Lung cancer, smoking patterns, and mutagen sensitivity in Mexican-Americans. J Natl Cancer Inst Monogr 18(18):29-33, 1995. PMID: 8562219.

Invited Articles

1. Wu X, Lu C, Chiang SS, Ajani JA. Pharmacogenetics in esophageal cancer. Semin Oncol 32(6 Suppl 9):S87-9, 12/2005. PMID: 16399440.
2. Spitz MR, Wu X, Mills G. Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol 23(2):267-75, 2005. PMID: 15637390.
3. Rebbeck TR, Spitz M, Wu X. Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet 5(8):589-97, 2004. PMID: 15266341.
4. Dinney CP, McConkey DJ, Millikan RE, Wu X , Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell 6:111-6, 2004. PMID: 15324694.

Editorials

1. CP Wen, X Wu. Stressing harms of physical inactivity to promote exercise. The Lancet 380(9838):192-193, 7/2012. e-Pub 7/2012.

Letters to the Editor

1. Kamat AM, Wu X . Statins and the effect of BCG on bladder cancer. N Engl J Med 356(12):1276-7, 3/2007. PMID: 17377172.

Last updated: 4/17/2013